Seeking Treatment

Finding a Treatment Location Near You

If you are a potential donor, please register with a donation center listed in our Donating Plasma Page.

If you are either a potential donor or are seeking treatment, and are trying to locate a hospital that provides convalescent plasma, we provide a link to hospitals that are using convalescent plasma.  The hospitals shown on this map have enrolled patients in the Expanded Access Program of the FDA.*  This map is available on the Mayo Clinic website and we here provide a program that allows you to use that map to find a treating hospital near you.

 *The Mayo Clinic-led expanded access program has discontinued new physician and new patient enrollments. COVID-19 convalescent plasma remains available through emergency use authorization.

 

Use the map below to locate institutions treating patients with convalescent plasma nearest you.

State:City:
Zip Code:

 

 

Patients and their Families Interested in Obtaining Convalescent Plasma Treatment

Below we explain the two ways in which the FDA has authorized convalescent plasma to be used in the US now.  These authorizations are required since convalescent plasma for treatment of COVID 19 patients is still viewed as experimental.

Under normal circumstances, any drug or treatment used in the healthcare setting must be proven to be safe and effective through scientifically designed randomized clinical trials. In urgent circumstances, however, the FDA can authorize use of an Investigational New Drug (IND), which COVID-19 convalescent plasma is, for treatment outside the scope of a trial. Trial work is described on this website on our clinical trials page under Health Care Providers, where all trials in the US of which we are aware are listed.

The Food and Drug Administration (FDA) has taken two steps to make convalescent plasma available to patients outside of the trial setting:

  1. Single Patient Emergency IND (eIND) On March 25, 2020 the FDA authorized compassionate use of convalescent plasma for patients severely ill with COVID-19 disease. The FDA form that is required to be completed for obtaining an eIND can be found on the FDA forms page.

  2. Expanded Access: On April 4, 2020, the FDA, working with multiple federal partners and academia, opened an expanded access protocol to facilitate access to COVID-19 convalescent plasma across the nation. For patients with serious or immediately life-threatening COVID-19, or who are at risk of becoming severely ill, but who are not eligible for or who are unable to participate in randomized clinical trials, can obtain access to convalescent plasma under this expanded access program. All treated patients should be registered at this Mayo Clinic Website.
  • What is Convalescent Plasma Treatment?

    When a person gets infected with a virus, that person’s body produces proteins called antibodies to fight off the virus. Those antibodies continue to circulate in the body well after the person has recovered and no longer has symptoms. These antibodies are present in a fraction of the blood called plasma.

    Plasma is routinely collected from healthy volunteers at blood donation sites for use as a treatment for a variety of diseases and traumas. Plasma donated by a person who was infected by the virus that causes COVID-19 and is fully recovered may contain antibodies that could be used to treat people who are currently infected with the virus.

  • What evidence is there that it will help?

    The use of antibody-rich convalescent plasma to treat or prevent serious infections, has been part of medical practice for more than a hundred years. It was a common treatment for bacterial infections before the discovery of antibiotics. More recently, other infectious diseases such as H1N1 influenza, SARS, and MERS have been treated with convalescent plasma with varying results.

    Small studies without control groups in China during the recent outbreak of COVID-19 there suggest that convalescent plasma improved outcomes. Until randomized trials are completed in the future, however, we will not know for sure that it works and, if it does, in what circumstances, and for whom.

  • Where is this treatment available?

    The FDA has designated COVID-19 convalescent plasma as a treatment that can be used in very severe COVID-19 disease. Groups of doctors and scientists are currently working to make this treatment available in the U.S. Please visit the FDA webpage to learn more. If you are interested in receiving convalescent plasma treatment, talk to your healthcare provider.

  • Where can I find more information?